CYP19A1 and obesity due to melanocortin 4 receptor deficiency: A combined approach, comprising aromatase inhibitors combined with antidiabetic, anti-inflammatory, and antioxidant drugs, plus progestins administered locally through an intrauterine device [66], may constitute a new targeted therapeutic approach, particularly in women that, by virtue of obesity, may also have an increased risk of surgical complications and, therefore, could not receive optimal surgery.